Why the study?
Do NOACs prevent stroke and systemic thromboembolism in patients with atrial fibrillation?
Do NOACs prevent stroke and systemic thromboembolism in patients with atrial fibrillation?
NOACs are the recommended therapy for stroke prevention in most patients with atrial fibrillation based on the 2018 EHRA guidance.
Answers are grounded in this paper and cite their sources.
NOACs remain first-line for stroke prevention in most AF patients; extends prior guidance across additional clinical scenarios.
In patients with AF, NOACs are recommended in the prevention of stroke and systemic thromboembolism in a vast majority of patients at risk, excluding only patients who underwent implanta-423 www.cardiologyjournal.org
No takes yet. Share an insight, caveat, or question.
Tomaszuk−Kazberuk et al. (2018) conducted a review in Atrial fibrillation. Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Vitamin K antagonists (VKAs) was evaluated. The 2018 EHRA Practical Guide provides updated clinical recommendations for the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation across various clinical scenarios.
Synapse has enriched 10 related papers. Consider them for comparative context: